Pfizer Acquire ReViral for $ 525 Millon and its Respiratory Syncytial Virus Therapeutic Candidates Sisunatovir
Synopsis : Under the terms of the agreement, Pfizer will acquire ReViral for a total consideration of up to $525 million, including…
Synopsis : Under the terms of the agreement, Pfizer will acquire ReViral for a total consideration of up to $525 million, including…
Synopsis : Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in…